EXCLUSIVE-Delays getting higher dose Wegovy to patients reported by US doctors
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Some U.S. patients taking the two highest doses of Novo Nordisk’s Wegovy weight-loss drug are facing difficulty filling their prescriptions, eight doctors around the country told Reuters this week, suggesting a new supply challenge for the popular medicine.
:max_bytes(150000):strip_icc():format(jpeg)/PaperworkatDesk-1a3837aec527439dbbf86d99a89611ba.jpg "2024 and 2025 Federal Income Tax Brackets, Standard Deductions, and Tax Rates")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1245836826-2b88234057c442f7bf5538ddb7f7584a.jpg "What It Would Take for the U.S. Dollar To Collapse")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1336655800-0cde652f461b4771aa45601032b5420b.jpg "Home Equity Loans and Divorce")
:max_bytes(150000):strip_icc():format(jpeg)/WhatIstheThree-YearRuleAug.262021-09d1295e78a743ecac4a31c6c042d52d.jpg "Reverse Mortgage Income Requirements")